Literature DB >> 25593053

Effect of aging on human mesenchymal stem cell therapy in ischemic cardiomyopathy patients.

Samuel Golpanian1, Jill El-Khorazaty2, Adam Mendizabal2, Darcy L DiFede1, Viky Y Suncion1, Vasileios Karantalis1, Joel E Fishman3, Eduard Ghersin3, Wayne Balkan1, Joshua M Hare4.   

Abstract

BACKGROUND: The role of patient age in the efficacy of mesenchymal stem cell (MSC) therapy in ischemic cardiomyopathy (ICM) is controversial.
OBJECTIVES: This study sought to determine whether the therapeutic effect of culture-expanded MSCs persists, even in older subjects.
METHODS: Patients with ICM who received MSCs via transendocardial stem cell injection (TESI) as part of the TAC-HFT (Transendocardial Autologous Cells in Ischemic Heart Failure) (n = 19) and POSEIDON (Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis) (n = 30) clinical trials were divided into 2 age groups: younger than 60 and 60 years of age and older. Functional capacity was measured by 6-min walk distance (6MWD) and quality of life using the Minnesota Living With Heart Failure Questionnaire (MLHFQ) score, measured at baseline, 6 months, and 1 year post-TESI. Various cardiac imaging parameters, including absolute scar size, were compared at baseline and 1 year post-TESI.
RESULTS: The mean 6MWD was similar at baseline and increased at 1 year post-TESI in both groups: 48.5 ± 14.6 m (p = 0.001) for the younger and 35.9 ± 18.3 m (p = 0.038) for the older participants (p = NS between groups). The older group exhibited a significant reduction in MLHFQ score (-7.04 ± 3.54; p = 0.022), whereas the younger than 60 age group had a borderline significant reduction (-11.22 ± 5.24; p = 0.058) from baseline (p = NS between groups). Although there were significant reductions in absolute scar size from baseline to 1 year post-TESI, the effect did not differ by age.
CONCLUSIONS: MSC therapy with TESI in ICM patients improves 6MWD and MLHFQ score and reduces myocardial infarction size. Importantly, older individuals did not have an impaired response to MSC therapy.
Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  heart failure; infarct size; ischemic heart disease

Mesh:

Year:  2015        PMID: 25593053      PMCID: PMC4405121          DOI: 10.1016/j.jacc.2014.10.040

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  41 in total

1.  Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI): final 5-year results suggest long-term safety and efficacy.

Authors:  David M Leistner; Ulrich Fischer-Rasokat; Jörg Honold; Florian H Seeger; Volker Schächinger; Ralf Lehmann; Hans Martin; Iris Burck; Carmen Urbich; Stefanie Dimmeler; Andreas M Zeiher; Birgit Assmus
Journal:  Clin Res Cardiol       Date:  2011-06-03       Impact factor: 5.460

2.  Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells.

Authors:  Karin Stenderup; Jeannette Justesen; Christian Clausen; Moustapha Kassem
Journal:  Bone       Date:  2003-12       Impact factor: 4.398

3.  Aging of progenitor cells: limitation for regenerative capacity?

Authors:  Stefanie Dimmeler; Mariuca Vasa-Nicotera
Journal:  J Am Coll Cardiol       Date:  2003-12-17       Impact factor: 24.094

4.  Measurable immune dysfunction and telomere attrition in long-term allogeneic transplant recipients.

Authors:  N L Lewis; M Mullaney; K F Mangan; T Klumpp; A Rogatko; D Broccoli
Journal:  Bone Marrow Transplant       Date:  2004-01       Impact factor: 5.483

5.  Transendocardial autologous bone marrow in chronic myocardial infarction using a helical needle catheter: 1-year follow-up in an open-label, nonrandomized, single-center pilot study (the TABMMI study).

Authors:  Luis M de la Fuente; Simon H Stertzer; Julio Argentieri; Eduardo Peñaloza; Jorge Miano; Benjamin Koziner; Cristian Bilos; Peter A Altman
Journal:  Am Heart J       Date:  2007-07       Impact factor: 4.749

6.  Psychometric properties of the Minnesota Living with Heart Failure Questionnaire (MLHF-Q).

Authors:  B Middel; J Bouma; M de Jongste; E van Sonderen; M G Niemeijer; H Crijns; W van den Heuvel
Journal:  Clin Rehabil       Date:  2001-10       Impact factor: 3.477

7.  Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction.

Authors:  Volker Schächinger; Sandra Erbs; Albrecht Elsässer; Werner Haberbosch; Rainer Hambrecht; Hans Hölschermann; Jiangtao Yu; Roberto Corti; Detlef G Mathey; Christian W Hamm; Tim Süselbeck; Birgit Assmus; Torsten Tonn; Stefanie Dimmeler; Andreas M Zeiher
Journal:  N Engl J Med       Date:  2006-09-21       Impact factor: 91.245

8.  Infarct size by contrast enhanced cardiac magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction or end-systolic volume index: prospective cohort study.

Authors:  E Wu; J T Ortiz; P Tejedor; D C Lee; C Bucciarelli-Ducci; P Kansal; J C Carr; T A Holly; D Lloyd-Jones; F J Klocke; R O Bonow
Journal:  Heart       Date:  2007-12-10       Impact factor: 5.994

9.  Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion.

Authors:  Melissa A Baxter; Robert F Wynn; Simon N Jowitt; J Ed Wraith; Leslie J Fairbairn; Ilaria Bellantuono
Journal:  Stem Cells       Date:  2004       Impact factor: 6.277

10.  Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial.

Authors:  Alan W Heldman; Darcy L DiFede; Joel E Fishman; Juan P Zambrano; Barry H Trachtenberg; Vasileios Karantalis; Muzammil Mushtaq; Adam R Williams; Viky Y Suncion; Ian K McNiece; Eduard Ghersin; Victor Soto; Gustavo Lopera; Roberto Miki; Howard Willens; Robert Hendel; Raul Mitrani; Pradip Pattany; Gary Feigenbaum; Behzad Oskouei; John Byrnes; Maureen H Lowery; Julio Sierra; Mariesty V Pujol; Cindy Delgado; Phillip J Gonzalez; Jose E Rodriguez; Luiza Lima Bagno; Didier Rouy; Peter Altman; Cheryl Wong Po Foo; Jose da Silva; Erica Anderson; Richard Schwarz; Adam Mendizabal; Joshua M Hare
Journal:  JAMA       Date:  2014-01-01       Impact factor: 56.272

View more
  26 in total

1.  Cell Therapy: Targeting Endogenous Repair Versus Remuscularization.

Authors:  Konstantinos E Hatzistergos; Joshua M Hare
Journal:  Circ Res       Date:  2015-09-25       Impact factor: 17.367

2.  Clinical research skills development program in cell-based regenerative medicine.

Authors:  Ivonne Hernandez Schulman; Viky Suncion; Vasileios Karantalis; Wayne Balkan; Joshua M Hare
Journal:  Stem Cells Transl Med       Date:  2014-12-29       Impact factor: 6.940

Review 3.  Mesenchymal Stem Cell-Based Therapy for Cardiovascular Disease: Progress and Challenges.

Authors:  Luiza Bagno; Konstantinos E Hatzistergos; Wayne Balkan; Joshua M Hare
Journal:  Mol Ther       Date:  2018-05-25       Impact factor: 11.454

Review 4.  Use of mesenchymal stem cells for therapy of cardiac disease.

Authors:  Vasileios Karantalis; Joshua M Hare
Journal:  Circ Res       Date:  2015-04-10       Impact factor: 17.367

5.  Multimodality Molecular Imaging of Cardiac Cell Transplantation: Part I. Reporter Gene Design, Characterization, and Optical in Vivo Imaging of Bone Marrow Stromal Cells after Myocardial Infarction.

Authors:  Natesh Parashurama; Byeong-Cheol Ahn; Keren Ziv; Ken Ito; Ramasamy Paulmurugan; Jürgen K Willmann; Jaehoon Chung; Fumiaki Ikeno; Julia C Swanson; Denis R Merk; Jennifer K Lyons; David Yerushalmi; Tomohiko Teramoto; Hisanori Kosuge; Catherine N Dao; Pritha Ray; Manishkumar Patel; Ya-Fang Chang; Morteza Mahmoudi; Jeff Eric Cohen; Andrew Brooks Goldstone; Frezghi Habte; Srabani Bhaumik; Shahriar Yaghoubi; Robert C Robbins; Rajesh Dash; Phillip C Yang; Todd J Brinton; Paul G Yock; Michael V McConnell; Sanjiv S Gambhir
Journal:  Radiology       Date:  2016-06-16       Impact factor: 11.105

Review 6.  Cardiac aging - Getting to the stem of the problem.

Authors:  Nirmala Hariharan; Mark A Sussman
Journal:  J Mol Cell Cardiol       Date:  2015-04-14       Impact factor: 5.000

Review 7.  Physiological Systems in Promoting Frailty.

Authors:  Laís R Perazza; Holly M Brown-Borg; LaDora V Thompson
Journal:  Compr Physiol       Date:  2022-04-26       Impact factor: 8.915

Review 8.  Clinical Studies of Cell Therapy in Cardiovascular Medicine: Recent Developments and Future Directions.

Authors:  Monisha N Banerjee; Roberto Bolli; Joshua M Hare
Journal:  Circ Res       Date:  2018-07-06       Impact factor: 17.367

Review 9.  Stimulating endogenous cardiac repair.

Authors:  Amanda Finan; Sylvain Richard
Journal:  Front Cell Dev Biol       Date:  2015-09-29

10.  The impact of patient sex on the response to intramyocardial mesenchymal stem cell administration in patients with non-ischaemic dilated cardiomyopathy.

Authors:  Victoria Florea; Angela C Rieger; Makoto Natsumeda; Bryon A Tompkins; Monisha N Banerjee; Ivonne H Schulman; Courtney Premer; Aisha Khan; Krystalenia Valasaki; Bettina Heidecker; Alejandro Mantero; Wayne Balkan; Raul D Mitrani; Joshua M Hare
Journal:  Cardiovasc Res       Date:  2020-11-01       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.